Pliant Therapeutics reports Q4 2023 net loss of $41.1M; positive bexotegrast data in PSC

PLIANT THERAPEUTICS, INC.

2023-FY EPS reported -$2.75 revenue$1,580,000

Net loss $41.1M vs $35.1M YoY; R&D expenses $33.2M (+32% YoY) driven by bexotegrast costs.
Cash $495.7M; expected to fund operations into H2 2026.
Positive 12-week data from 320 mg cohort of INTEGRIS-PSC: reduced ELF and PRO-C3, improved bile flow.
BEACON-IPF Phase 2b enrolling ~270 patients; 24-week PSC data expected mid-2024.
PLN-101095 Phase 1 solid tumors enrolling third cohort; DMD regulatory filing expected Q1 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

PLIANT THERAPEUTICS, INC. reported fourth quarter ended December 31, 2023 results: net income Net loss was $41.1 million.

Period: fourth quarter ended December 31, 2023
Net income: Net loss was $41.1 million
Result: reported results

Exact text from the filing

Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, today provided a corporate update and reported fourth quarter 2023 financial results.

View on SEC.gov

39 earnings releases filed in the last 30 days. Browse all earnings releases →

PLIANT THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001746473-24-000041

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.